SUPPLEMENTARY TABLE S1 PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to Systematic Reviews from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 2015 4:1

| Section/topic         | # | Checklist item                                                                 | Information reported | Page submitted manuscript |
|-----------------------|---|--------------------------------------------------------------------------------|-----------------------|---------------------------|
|                        |   |                                                                                 | Yes | No |                             |
| ADMINISTRATIVE INFORMATION |   |                                                                                 |               |                           |
| Title                 |   |                                                                                 |               |                           |
| Identification        | 1a| Identify the report as a protocol of a systematic review                        | ✗     |   | 1                           |
| Update                | 1b| If the protocol is for an update of a previous systematic review, identify as such | ✗     |   | NA                          |
| Registration          | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | ✗     |   | 3                           |
| Authors               |   |                                                                                 |               |                           |
| Contact               | 3a| Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | ✗     |   | 1                           |
| Contributions         | 3b| Describe contributions of protocol authors and identify the guarantor of the review | ✗     |   | 25                          |
| Amendments            | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | ✗     |   | NA                          |
| Support               |   |                                                                                 |               |                           |
| Sources               | 5a| Indicate sources of financial or other support for the review                    | ✗     |   | 25                          |
| Sponsor               | 5b| Provide name for the review funder and/or sponsor                                | ✗     |   | NA                          |
| Role of sponsor/funder| 5c| Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | ✗     |   | NA                          |
| INTRODUCTION          |   |                                                                                 |               |                           |
| Rationale             | 6 | Describe the rationale for the review in the context of what is already known    | ✗     |   | 3                           |
| Objectives            | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | ✗     |   | 3                           |
| METHODS               |   |                                                                                 |               |                           |
| Section/topic                          | #  | Checklist item                                                                 | Information reported | Page submitted manuscript |
|--------------------------------------|----|--------------------------------------------------------------------------------|----------------------|---------------------------|
| Eligibility criteria                 | 8  | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | ☒ No                  | 3,4                       |
| Information sources                  | 9  | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | ☒ No                  | 3                        |
| Search strategy                      | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | ☒ No                  | Supplement Appendix 1     |
| **STUDY RECORDS**                    |    |                                                                                  |                      |                           |
| Data management                      | 11a| Describe the mechanism(s) that will be used to manage records and data throughout the review | ☒ No                  | 4                        |
| Selection process                    | 11b| State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | ☒ No                  | 4                        |
| Data collection process              | 11c| Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | ☒ No                  | 4                        |
| Data items                           | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | ☒ No                  | 4                        |
| Outcomes and prioritization          | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | ☒ No                  | 4                        |
| Risk of bias in individual studies   | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | ☒ No                  | 4                        |
| **DATA**                             |    |                                                                                  |                      |                           |
| Synthesis                            | 15a| Describe criteria under which study data will be quantitatively synthesized      | ☒ Yes                 | NA                       |
|                                     | 15b| If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$, Kendall’s tau) | ☒ Yes                 | NA                       |
|                                     | 15c| Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | ☒ Yes                 | NA                       |
|                                     | 15d| If quantitative synthesis is not appropriate, describe the type of summary planned | ☒ No                  | 5                        |
| Meta-bias(es)                        | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | ☒ No                  | NA                       |
| Section/topic                     | #  | Checklist item                                                                 | Information reported | Page submitted manuscript |
|----------------------------------|----|--------------------------------------------------------------------------------|-----------------------|--------------------------|
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | No                    | NA                       |